Demethylating agent 5-aza-2'-deoxycytidine activates HLA-G expression in human leukemia cell lines.
HLA-G is a non-classical HLA class I antigen primarily expressed in the extravillous cytotrophoblast. HLA-G can also be expressed at some pathological circumstances and may thus contribute to inhibition of efficient immune responses. Complex regulation of HLA-G expression also involves epigenetic mechanisms as DNA methylation. Here we demonstrate that treatment with demethylating agent 5-aza-2'-deoxycytidine (AdC) resulted in HLA-G transcription in 18 out of 20 examined leukemia cell lines. HLA-G protein synthesis was detected in 10 cell lines expressing significant level of HLA-G transcripts following AdC treatment.
Poláková
K
K
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Bandzuchová
E
E
Kuba
D
D
Russ
G
G
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D000077209:Decitabine; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006680:HLA Antigens / Q000096:biosynthesis*; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis*; D006801:Humans; D007938:Leukemia / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000964:Antimetabolites, Antineoplastic; D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; D000077209:Decitabine; D001374:Azacitidine